<DOC>
	<DOC>NCT01867307</DOC>
	<brief_summary>Single center, 14-day, open-label trial to examine the effect of 25 mg q.d. empagliflozin on kinetics of renal glucose reabsorption in patients diagnosed with type 2 diabetes mellitus and healthy controls</brief_summary>
	<brief_title>Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criteria: 1. T2DM patients and healthy controls aged =18 to &lt;70 at Visit 1. 2. Patients diagnosed with T2DM according to the American Diabetes Association criteria prior to informed consent who are drugna√Øve 3. T2DM patients on a stable dose of allowed concomitant medications (as determined by investigator) for 30 days prior to entering the study. 4. T2DM patients with HbA1c between &gt;7 and &lt;10.0% (&gt;53 mmol/mol and &lt;86 mmol/mol) at Visit Exclusion criteria: 1. Patients with type 1 diabetes mellitus. 2. Patients with uncontrolled hyperglycemia with a fasting plasma glucose level greater than 240 mg/dl after an overnight fast. 3. Patients with a history of clinically significant heart disease (New York Heart Classification greater than class 3; more than nonspecific STT wave changes on the ECG), peripheral vascular disease (history of claudication), or pulmonary disease as determined by investigator. 4. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>